EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
Authors
Keywords
Cetuximab, Metastatic colorectal cancer, Amphiregulin, Epidermal growth factor, Transforming growth factor-α, Heparin-binding epidermal growth factor
Journal
Targeted Oncology
Volume 9, Issue 3, Pages 205-214
Publisher
Springer Nature
Online
2013-07-02
DOI
10.1007/s11523-013-0284-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
- (2013) George Pentheroudakis et al. BMC CANCER
- Identification of a Poor-PrognosisBRAF-Mutant–Like Population of Patients With Colon Cancer
- (2012) Vlad Popovici et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
- (2012) Daniel J Freeman et al. Molecular Cancer
- Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17
- (2010) S. Van Schaeybroeck et al. CANCER RESEARCH
- Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting “Lost in TranslationAL”?
- (2010) Chiara Cremolini et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study
- (2010) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Dose-Dependent Increases in Circulating TGF- and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent
- (2009) A. J. Mutsaers et al. CLINICAL CANCER RESEARCH
- PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
- (2009) Fotios Loupakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2009) Bart Jacobs et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
- (2008) K. Yonesaka et al. CLINICAL CANCER RESEARCH
- In Reply
- (2008) Christopher T. Harbison et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started